InVitae Corp (N:NVTA)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 1400 16th St
Tel: N/A
IR: See website
Key People
Sean E. George
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Shelly D. Guyer
Chief Financial Officer
Kenneth Knight
Chief Operating Officer
Robert F. Werner
Chief Accounting Officer
Thomas R. Brida
General Counsel, Secretary
Robert L. Nussbaum
Chief Medical Officer
Katherine A. Stueland
Chief Commercial Officer
Business Overview
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.
Financial Overview
For the three months ended 31 March 2020, InVitae Corp revenues increased 58% to $64.2M. Net loss increased from $37.7M to $98.5M. Revenues reflect United States segment increase of 59% to $59.8M, Rest of World segment increase of 66% to $3.2M. Higher net loss reflects Stock-based Compensation in R&D increase from $1.8M to $22.2M (expense), Selling and Marketing - Balancing value increase of 76% to $40.3M (expense).
Employees: 1,500 as of Mar 31, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $4,164M as of Mar 31, 2020
Annual revenue (TTM): $240.52M as of Mar 31, 2020
EBITDA (TTM): -$286.71M as of Mar 31, 2020
Net annual income (TTM): -$302.82M as of Mar 31, 2020
Free cash flow (TTM): -$200.16M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 125,012,944 as of May 1, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization